Patent: 9,931,382

Summary for Patent: 9,931,382

Title:	Treatment of ophthalmic conditions
Abstract:	Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the pharmaceutical compositions such as hyaluronase allow the cornea of the eye to be molded in order to correct the refractive error of the eye. The contact lenses and the pharmaceutical composition induce a change in the radius of curvature of the anterior surface of the cornea, thereby correcting the refractive error of the eye. One advantage of the inventive technique is that the patient with his or her own individual visual needs guides the treatment until the patient near and far visual needs are met. The present invention also provides for kits, which contain molding contact lenses, pharmaceutical composition suitable for delivery to the eye, and instructions, useful in the inventive system.
Inventor(s):	Osio Sancho; Alberto (Mexico, MX)
Assignee:	Osio Corporation (Coronado, CA)
Application Number:	15/398,529
Patent Claims:	see list of patent claims

Details for Patent 9,931,382

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2023-12-19
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2023-12-19
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2023-12-19
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2023-12-19
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2023-12-19